{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:24:46Z","timestamp":1754151886877,"version":"3.41.2"},"reference-count":132,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ad.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:58:55Z","timestamp":1748458735000},"page":"T740-T754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] An Overview of Actinic Keratoses: Understanding Etiology, Diagnosis, and Treatment Approaches"],"prefix":"10.1016","volume":"116","author":[{"given":"J.","family":"Ca\u00f1ueto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Turri\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ferr\u00e1ndiz-Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.05.015_bib0665","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ad.2009.11.007","article-title":"Dermatology service utilization and reasons for consultation by Spanish and immigrant patients in the region served by Hospital Son Ll\u00e0tzer, Palma de Majorca Spain","volume":"101","author":"Taberner","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib0670","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.ejcskn.2023.100004","article-title":"German S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d \u2013 long version of the update 2023","volume":"1","author":"Leiter","year":"2023","journal-title":"EJC Skin Cancer"},{"key":"10.1016\/j.ad.2025.05.015_bib0675","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/bjd\/ljad371","article-title":"The global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis","volume":"190","author":"George","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0680","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2016.05.016","article-title":"Prevalence of actinic keratosis among dermatology outpatients in Spain","volume":"107","author":"Ferr\u00e1ndiz","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib0685","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2133.2010.10118.x","article-title":"Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0690","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of care for the management of actinic keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0695","first-page":"691","article-title":"P53, p16 and Ki67 immunoexpression in cutaneous squamous cell carcinoma and its precursor lesions","volume":"57","author":"Marinescu","year":"2016","journal-title":"Rom J Morphol Embryol"},{"key":"10.1016\/j.ad.2025.05.015_bib0700","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis \u2013 International League of Dermatological Societies in cooperation with the European Dermatology Forum \u2013 Short version","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0705","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"Marks","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.05.015_bib0710","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ad.2025.05.015_bib0715","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: a systematic review","volume":"169","author":"Werner","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0720","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2016.07.016","article-title":"Precancerous skin lesions","volume":"108","author":"Ferr\u00e1ndiz","year":"2017","journal-title":"Actas Dermosifiliogr"},{"year":"2011","series-title":"Guideline on actinic keratoses, developed by the Guideline Subcommittee \u201cActinic Keratoses\u201d of the European Dermatology Forum","author":"Stockfleth","key":"10.1016\/j.ad.2025.05.015_bib0725"},{"key":"10.1016\/j.ad.2025.05.015_bib0730","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ad.2013.11.013","article-title":"Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2025.05.015_bib0735","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2133.2007.08275.x","article-title":"Noninvasive diagnostic tools for nonmelanoma skin cancer","volume":"157","author":"Ulrich","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0740","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-G","article-title":"A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck","volume":"24","author":"Olsen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0745","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","article-title":"Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis","volume":"158","author":"Ahmady","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0750","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jdv.14652","article-title":"Defining the actinic keratosis field: a literature review and discussion","volume":"32","author":"Figueras Nart","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0755","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archdermatol.2012.1060","article-title":"Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis","volume":"148","author":"Huerta-Brogeras","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0760","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/jcm12031063","article-title":"Dermoscopy of actinic keratosis: is there a true differentiation between non-pigmented and pigmented lesions?","volume":"12","author":"Sgouros","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0765","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2133.2006.07426.x","article-title":"Dermoscopy of facial nonpigmented actinic keratosis","volume":"155","author":"Zalaudek","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0770","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/bjd.14355","article-title":"Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis","volume":"174","author":"Lallas","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0775","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2021.03.111","article-title":"Evaluation of dermatoscopic criteria for early detection of squamous cell carcinoma arising on an actinic keratosis","volume":"86","author":"Papageorgiou","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0780","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archdermatol.2009.134","article-title":"Reflectance confocal microscopy criteria for squamous cell carcinomas and actinic keratoses","volume":"145","author":"Rishpon","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0785","first-page":"610","article-title":"Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses","volume":"34","author":"Ulrich","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2025.05.015_bib0790","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/lsm.20573","article-title":"Using optical coherence tomography to evaluate skin sun damage and precancer","volume":"39","author":"Korde","year":"2007","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0795","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers16030484","article-title":"Digitally enhanced methods for the diagnosis and monitoring of treatment responses in actinic keratoses: a new avenue in personalized skin care","volume":"16","author":"Soare","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ad.2025.05.015_bib0800","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/exd.12074","article-title":"Imaging actinic keratosis by high-definition optical coherence tomography histomorphologic correlation: a pilot study","volume":"22","author":"Boone","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0805","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/153303460300200605","article-title":"Investigating sun-damaged skin and actinic keratosis with optical coherence tomography: a pilot study","volume":"2","author":"Barton","year":"2003","journal-title":"Technol Cancer Res Treat"},{"issue":"Suppl. 3","key":"10.1016\/j.ad.2025.05.015_bib0810","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.07860.x","article-title":"Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification","volume":"156","author":"R\u00f6wert-Huber","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2025.05.015_bib0815","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2007.08267.x","article-title":"Pathology and pathobiology of actinic (solar) keratosis\u2014an update","volume":"157","author":"Roewert-Huber","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0820","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jdv.13626","article-title":"Actinic keratosis: correlation between clinical and histological classification systems","volume":"30","author":"Schmitz","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0825","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin","volume":"29","author":"Fern\u00e1ndez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0830","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdv.14512","article-title":"Actinic keratoses show variable histological basal growth patterns\u2014a proposed classification adjustment","volume":"32","author":"Schmitz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0835","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.16536","article-title":"Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses","volume":"180","author":"Schmitz","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0840","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jdv.14267","article-title":"A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index","volume":"31","author":"Dirschka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0845","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2340\/00015555-2710","article-title":"A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity","volume":"97","author":"Dr\u00e9no","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0850","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12955-015-0295-4","article-title":"Health related quality of life in patients with actinic keratosis\u2014an observational study of patients treated in dermatology specialist care in Denmark","volume":"13","author":"Tennvall","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2025.05.015_bib0855","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ad.2018.01.004","article-title":"Quality of life behaviour and attitudes towards actinic keratosis in Spain: the PIQA Study","volume":"109","author":"Longo","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib0860","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000349992","article-title":"Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis","volume":"226","author":"Gholam","year":"2013","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.ad.2025.05.015_bib0865","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjd.12036","article-title":"Assessing the influence of actinic keratosis on patients\u2019 quality of life: the AKQoL questionnaire: the AKQoL questionnaire","volume":"168","author":"Esmann","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0870","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ad.2016.03.003","article-title":"Adaptation and validation of the Spanish version of the Actinic Keratosis Quality of Life questionnaire","volume":"107","author":"Longo Imedio","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib0875","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJM199310143291602","article-title":"Reduction of solar keratoses by regular sunscreen use","volume":"329","author":"Thompson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0880","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","article-title":"Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects","volume":"94","author":"Reinehr","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0885","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.3390\/molecules27185998","article-title":"Photolyase production and current applications: a review","volume":"27","author":"Ram\u00edrez-Gamboa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ad.2025.05.015_bib0890","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.piel.2016.02.008","article-title":"Estudio observacional sobre la efectividad y tolerabilidad de un producto t\u00f3pico con fotoliasa y filtros solares en pacientes con queratosis act\u00ednicas tratados con crioterapia en condiciones de uso habitual","volume":"31","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2016","journal-title":"Piel"},{"key":"10.1016\/j.ad.2025.05.015_bib0895","doi-asserted-by":"crossref","DOI":"10.5070\/D3231033687","article-title":"The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multiple actinic keratoses: a case-series","volume":"23","author":"Navarrete-Dechent","year":"2017","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2025.05.015_bib0900","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13555-019-0294-1","article-title":"Review of clinical evidence over 10 years on prevention and treatment of a film-forming medical device containing photolyase in the management of field cancerization in actinic keratosis","volume":"9","author":"Puig","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.05.015_bib0905","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.abd.2021.06.005","article-title":"Efficacy of sunscreen with photolyase or regular sunscreen associated with topical antioxidants in treating advanced photodamage and cutaneous field cancerization: a randomized clinical trial","volume":"97","author":"Alvares","year":"2022","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0910","article-title":"Actinic keratosis in solid organ transplant recipients: a medical literature review","author":"Morell\u00f3 Vicente","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib0915","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/DSS.0000000000002072","article-title":"Use of topical and systemic retinoids in solid organ transplant recipients: update and review of the current literature","volume":"45","author":"Herold","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2025.05.015_bib0920","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.piel.2013.01.005","article-title":"Tratamiento de las queratosis act\u00ednicas en pacientes trasplantados de \u00f3rgano s\u00f3lido","volume":"28","author":"Ferr\u00e1ndiz-Pulido","year":"2013","journal-title":"Piel"},{"key":"10.1016\/j.ad.2025.05.015_bib0925","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0930","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for skin-cancer chemoprevention in transplant recipients","volume":"388","author":"Allen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0935","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jdv.19897","volume":"38","author":"Kandolf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0940","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1038\/s41598-022-09722-8","article-title":"Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials","volume":"12","author":"Steeb","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ad.2025.05.015_bib0945","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","article-title":"Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology","volume":"28","author":"Dirschka","year":"2017","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2025.05.015_bib0950","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/jcm9051438","article-title":"Treatment motivations and expectations in patients with actinic keratosis: a German-wide multicenter, cross-sectional trial","volume":"9","author":"Steeb","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2025.05.015_bib0955","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracilo treatment for actinic keratosis\u2014a systematic review of randomized controlled trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0960","doi-asserted-by":"crossref","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe","volume":"9","author":"Vegter","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2025.05.015_bib0965","first-page":"CD004415","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2025.05.015_bib0970","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jid.2020.06.021","article-title":"Interventions for actinic keratosis in nonscalp and nonface localizations: results from a systematic review with network meta-analysis","volume":"141","author":"Steeb","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0975","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/bjd.15272","article-title":"Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis","volume":"176","author":"Holzer","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib0980","first-page":"17","article-title":"Dermabrasion for prophylaxis and treatment of actinic keratoses","volume":"22","author":"Coleman","year":"1996","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al"},{"key":"10.1016\/j.ad.2025.05.015_bib0985","unstructured":"CIMA: ficha t\u00e9cnica Solaraze 30mg\/g gel [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/73714\/FT_73714.html#6 [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib0990","doi-asserted-by":"crossref","first-page":"164","DOI":"10.23736\/S2784-8671.21.07111-5","article-title":"Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care","volume":"157","author":"Perino","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib0995","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","article-title":"A review of existing therapies for actinic keratosis: current status and future directions","volume":"23","author":"Del Regno","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1000","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1005","unstructured":"CIMA: ficha t\u00e9cnica Actikerall 5mg\/g+100 mg\/g soluci\u00f3n cut\u00e1nea [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/77675\/FT_77675.html [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1010","unstructured":"CIMA: ficha t\u00e9cnica Tolak 40 mg\/g crema [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/84849\/FT_84849.html#6 [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.05.015_bib1020","first-page":"1218","article-title":"Efficacy safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis","volume":"15","author":"Dohil","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ad.2025.05.015_bib1030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36849\/JDD.6632","article-title":"Use of topical calcipotriol plus 5-fluorouracil in the treatment of actinic keratosis: a systematic review","volume":"21","author":"Mohney","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1035","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaad.2020.07.010","article-title":"Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: a retrospective study","volume":"84","author":"Moore","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1040","doi-asserted-by":"crossref","first-page":"e125476","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ad.2025.05.015_bib1045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1684\/ejd.2017.3128","article-title":"5-fluorouracil chemowraps for the treatment of multiple actinic keratoses","volume":"27","author":"Peuvrel","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1050","unstructured":"CIMA: ficha t\u00e9cnica Aldara 5% crema [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/98080001\/FT_98080001.html [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1055","unstructured":"CIMA: ficha t\u00e9cnica Zyclara 3,75% crema [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/12783002\/FT_12783002.html [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ad.2017.10.008","article-title":"A 12-day course of imiquimod 5% for the treatment of actinic keratosis: effectiveness and local reactions","volume":"109","author":"Serra-Guill\u00e9n","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib1075","unstructured":"Picato. European Medicines Agency [WWW Document]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/picato [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1080","unstructured":"CIMA: ficha t\u00e9cnica Klisyri 10 mg\/g pomada [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211558001\/FT_1211558001.html [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ad.2021.07.006","article-title":"Tirbanibulina: revisi\u00f3n de su mecanismo de acci\u00f3n novedoso y de c\u00f3mo encaja en el tratamiento de la queratosis act\u00ednica","volume":"113","author":"Gilaberte","year":"2022","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib1090","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for actinic keratosis: insights into the mechanism of action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1095","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.05.015_bib1100","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/jcm11061654","article-title":"Comparative efficacy and safety of tirbanibulin for actinic keratosis of the face and scalp in Europe: a systematic review and network meta-analysis of randomized controlled trials","volume":"11","author":"Heppt","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2025.05.015_bib1105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.25251\/skin.7.3.3","article-title":"Clinician- and patient-reported outcomes with tirbanibulin 1% treatment for actinic keratosis in routine clinical practice across the U.S. (PROAK Study)","volume":"7","author":"Schlesinger","year":"2023","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.ad.2025.05.015_bib1110","unstructured":"EADO2024Book_of_Abstracts.pdf. Available from: https:\/\/eado2024.com\/wp-content\/uploads\/2024\/04\/EADO2024Book_of_Abstracts.pdf [accessed 22.4.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.1368","article-title":"Pharmacokinetics safety, and tolerability of a single 5-day treatment of tirbanibulin ointment 1% in 100cm2: a phase 1 maximal-use trial in patients with actinic keratosis","volume":"13","author":"DuBois","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ad.2025.05.015_bib1120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdin.2024.07.001","article-title":"Safety and tolerability of tirbanibulin ointment 1% treatment on 100cm2 of the face or scalp in patients with actinic keratosis: a phase 3 study","volume":"17","author":"Bhatia","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ad.2025.05.015_bib1125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ad.2015.06.001","article-title":"Spanish-Portuguese consensus statement on use of daylight-mediated photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratosis","volume":"106","author":"Gilaberte","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib1130","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.16017","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019. Part 1: Treatment delivery and established indications\u2014actinic keratoses. Bowen's disease and basal cell carcinomas","volume":"33","author":"Morton","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib1135","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.pdpdt.2022.102858","article-title":"Bringing the gentle properties of daylight photodynamic therapy indoors: a systematic review of efficacy and safety","volume":"39","author":"Heerfordt","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.ad.2025.05.015_bib1140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.16044","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019. Part 2: Emerging indications\u2014field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"34","author":"Morton","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib1145","unstructured":"CIMA: ficha t\u00e9cnica Ameluz 78 mg\/g gel [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/11740001\/FT_11740001.html [accessed 22.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1150","unstructured":"CIMA: ficha t\u00e9cnica METVIX 160 mg\/g CREMA [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/64968\/FT_64968.html [accessed 22.3.24]"},{"key":"10.1016\/j.ad.2025.05.015_bib1155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pdpdt.2018.10.010","article-title":"Conventional versus daylight photodynamic therapy for actinic keratosis: a randomized and prospective study in China","volume":"24","author":"Zhu","year":"2018","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.ad.2025.05.015_bib1160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ad.2013.10.021","article-title":"Terapia fotodin\u00e1mica con luz de d\u00eda en Espa\u00f1a: ventajas y limitaciones","volume":"105","author":"P\u00e9rez-P\u00e9rez","year":"2014","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2025.05.015_bib1165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00403-019-02028-2","article-title":"Combined daylight and conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a new and efficient approach","volume":"312","author":"Salido-Vallejo","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2025.05.015_bib1170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaad.2018.09.021","article-title":"Laser-assisted photodynamic therapy for actinic keratosis: a systematic review and meta-analysis","volume":"80","author":"Steeb","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjd.17435","article-title":"Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis","volume":"180","author":"Heppt","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1180","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jdv.15459","article-title":"Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis","volume":"33","author":"Heppt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib1185","doi-asserted-by":"crossref","first-page":"104069","DOI":"10.1016\/j.pdpdt.2024.104069","article-title":"Pre-treatment with topical 5-fluorouracilo increases the efficacy of daylight photodynamic therapy for actinic keratoses\u2014a randomized controlled trial","volume":"46","author":"Wiegell","year":"2024","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.ad.2025.05.015_bib1190","doi-asserted-by":"crossref","first-page":"543","DOI":"10.31128\/AJGP-11-22-6600","article-title":"Role of volumetric modulated arc therapy in skin field cancerisation","volume":"52","author":"Mazzoni","year":"2023","journal-title":"Aust J Gen Pract"},{"key":"10.1016\/j.ad.2025.05.015_bib1195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000521067","article-title":"Radiotherapy, utilizing volumetric modulated arc therapy, for extensive skin field cancerization: a retrospective case series assessing efficacy, safety, and cosmetic outcomes at 12 months after treatment","volume":"14","author":"Spelman","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1200","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jamadermatol.2020.2327","article-title":"Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses squamous cell carcinoma, and basal cell carcinoma: a systematic review","volume":"156","author":"Schauder","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjd.17148","article-title":"Local interventions for actinic keratosis in organ transplant recipients: a systematic review","volume":"180","author":"Heppt","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1210","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients: a Delphi Consensus Statement","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil 5%, cream: a randomized clinical trial","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1220","unstructured":"CIMA: ficha t\u00e9cnica Solacutan 30mg\/g gel [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/81761\/FT_81761.html#6 [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1225","unstructured":"CIMA: ficha t\u00e9cnica diclofenaco Teva 30mg\/g gel [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/83054\/FT_83054.html#6 [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1230","unstructured":"CIMA: ficha t\u00e9cnica Zorequin 30 mg\/g gel [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/83055\/FT_83055.html#6 [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1235","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/bjd.12844","article-title":"A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp","volume":"170","author":"Zane","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracilo in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: Histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jdv.15868","article-title":"Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials","volume":"34","author":"Gollnick","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib1250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjd.16048","article-title":"Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp","volume":"178","author":"Stockfleth","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2230.2010.03999.x","article-title":"Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses","volume":"36","author":"Akarsu","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1265","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09546630701818870","article-title":"Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis","volume":"19","author":"Kose","year":"2008","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2025.05.015_bib1270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1440-0960.1997.tb01693.x","article-title":"Topical diclofenac\/hyaluronic acid gel in the treatment of solar keratoses","volume":"38","author":"McEwan","year":"1997","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1275","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","article-title":"Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group","volume":"26","author":"Pflugfelder","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.015_bib1280","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1590\/abd1806-4841.20132083","article-title":"Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracilo","volume":"88","author":"Segatto","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1285","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1290","unstructured":"CIMA: ficha t\u00e9cnica Imikeraderm 50 mg\/g crema [WWW Document]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/88034\/FT_88034.html [accessed 18.3.24]."},{"key":"10.1016\/j.ad.2025.05.015_bib1295","first-page":"1432","article-title":"A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes","volume":"10","author":"Foley","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1300","first-page":"144","article-title":"Comparison of 5% 5-fluorouracilo cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for 2 3-week cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1310","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for 2 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1315","first-page":"285","article-title":"Efficacy and safety of imiquimod 3.75% from lmax in actinic keratosis according to fitzpatrick skin type","volume":"15","author":"Alomar","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.015_bib1320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T08:01:54Z","timestamp":1753084914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025003758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":132,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001731025003758"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.015","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] An Overview of Actinic Keratoses: Understanding Etiology, Diagnosis, and Treatment Approaches","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.02.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}